Pediatric catheter ablation at the beginning of the 21st century: results from the European Multicenter Pediatric Catheter Ablation Registry 'EUROPA'.


Journal

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology
ISSN: 1532-2092
Titre abrégé: Europace
Pays: England
ID NLM: 100883649

Informations de publication

Date de publication:
08 03 2021
Historique:
received: 27 05 2020
accepted: 29 09 2020
pubmed: 24 11 2020
medline: 10 8 2021
entrez: 23 11 2020
Statut: ppublish

Résumé

Contemporary data from prospective multicentre registries on catheter ablation in pediatric patients are sparse. Aim of the European Pediatric Catheter Ablation Registry EUROPA was to contribute data to fill this gap of knowledge. From July 2012 to June 2017, data on catheter ablation in pediatric patients (≤18 years of age) including a 1-year follow-up from five European pediatric EP centres were collected prospectively. A total of 683 patients (mean age 12.4 ± 3.9 years, mean body weight 50.2 ± 19 kg) were enrolled. Target tachycardia was WPW/atrioventricular-nodal re-entrant tachycardia (AVRT) in 380 (55.7%) patients, AVNRT in 230 (33.8%) patients, ventricular tachycardia (VT) in 24 (3.5) patients, focal atrial tachycardia (FAT) in 20 (2.9%) patients, IART in 14 (2%) patients, and junctional ectopic tachycardia in 3 (0.45) patients. Overall procedural success was 95.6%. Compared with all other substrates, success was significantly lower in FAT patients (80%, n = 16, P = 0.001). Mean procedure duration was 136 ± 67 min and mean fluoroscopy time was 4.9 ± 6.8 min. Major complications occurred in 0.7% of the patients. No persisting AV block requiring permanent pacing was reported. At 1-year follow-up (605/683 patients, 95%), tachycardia recurrence was reported in 7.8% of patients. Recurrence after VT ablation (33%) was significantly higher (P = 0.001) than after ablation of all other substrates. The present study proves overall high efficacy and safety of catheter ablation of various tachycardia substrates in pediatric patients. Of note, complication rate was exceptionally low. Long-term success was high except for patients after VT ablation.

Identifiants

pubmed: 33227133
pii: 5998958
doi: 10.1093/europace/euaa325
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

431-440

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Auteurs

Ulrich Krause (U)

Department of Pediatric Cardiology and Intensive Care Medicine, University Medical Center, Georg-August-University, Göttingen 37099, Germany.

Thomas Paul (T)

Department of Pediatric Cardiology and Intensive Care Medicine, University Medical Center, Georg-August-University, Göttingen 37099, Germany.

Paolo Della Bella (PD)

Arrhyhtmia Department, Ospedale San Raffaele, Milano, 20132, Italy.

Simone Gulletta (S)

Arrhyhtmia Department, Ospedale San Raffaele, Milano, 20132, Italy.

Roman A Gebauer (RA)

Pediatric Cardiology, Heart Center, University of Leipzig, Leipzig, Germany.

Christian Paech (C)

Pediatric Cardiology, Heart Center, University of Leipzig, Leipzig, Germany.

Peter Kubus (P)

Children's Heart Centre, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, 15006, Czech Republic.

Jan Janousek (J)

Children's Heart Centre, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, 15006, Czech Republic.

Paola Ferrari (P)

Unita di Elettrofisiologia ed Elettrostimolazione Cardiaca, Ospedale Papa Giovanni XXIII, Bergamo, 24127, Italy.

Paolo De Filippo (P)

Unita di Elettrofisiologia ed Elettrostimolazione Cardiaca, Ospedale Papa Giovanni XXIII, Bergamo, 24127, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH